Nicholas C. Turner, MD | Authors

Adding Palbociclib Delays Progression in HR-Positive Breast Cancer

June 02, 2015

In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.